Amgen (CHIX:AMGD) Deferred Tax: €-447 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:AMGD Amgen Inc CHIX:AMGD
80 GF Score
Price €285.00
GF Value €266.26
! 8 Warning Signs
View Full Analysis

What is Amgen Deferred Tax?

Amgen CHIX:AMGD 80 Deferred Tax is €-447 Mil as of Jun. 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 80/100 and a GF Value™ of €266.26. The stock has 8 warning signs investors should review.

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Amgen's change in deferred tax for the three months ended in Jun. 2026 was €-253 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Jun. 2026 was €-447 Mil.

Amgen Deferred Tax Historical Data

* Premium members only.

The historical data trend for Amgen's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amgen Deferred Tax Chart

Amgen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only -400.91 -1,130.91 -1,167.34 -1,172.74 -615.73

Amgen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -365.87 -25.56 -16.23 -152.24 -252.59
CHIX:AMGD
80GF Score
Amgen Inc CHIX:AMGD
Deferred Tax is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amgen Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-447 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Deferred Tax →
What does a Deferred Tax of €-447 Mil mean?
Amgen (CHIX:AMGD) has a Deferred Tax of €-447 Mil as of Jun. 2026. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for Amgen.
Is Amgen's Deferred Tax too high?
Amgen's current Deferred Tax is €-447 Mil. Overall, Amgen has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Amgen's Deferred Tax compare to GILD and PFE?
Amgen's Deferred Tax of €-447 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Deferred Tax for a Drug Manufacturers company?
A good Deferred Tax depends on the Drug Manufacturers industry context. However, Deferred Tax should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Deferred Tax mean?
A high Deferred Tax can signal that a stock is expensive relative to its fundamentals. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for Amgen. Amgen's current Deferred Tax is €-447 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Amgen (CHIX:AMGD) has a current Deferred Tax of €-447 Mil. The stock's GF Value™ is €266.26, compared to a current price of €285.00 — trading 7% above its estimated fair value. The current Deferred Tax is €-447 Mil. Amgen's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Deferred Tax calculated?
Deferred Tax is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current Deferred Tax is €-447 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amgen (CHIX:AMGD) Overvalued in 2026?

Based on GuruFocus' analysis, Amgen stock appears to be overvalued. The current stock price of €285.00 is trading 7% above its estimated GF Value™ of €266.26.

Key valuation signals for CHIX:AMGD:

  • Deferred Tax: €-447 Mil
  • GF Value™: €266.26 vs. price of €285.00 (7% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amgen Business Description

Address One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
80GF Score

Get the complete analysis for CHIX:AMGD

Deferred Tax is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€285.00
Price
€266.26
GF Value